Mission Therapeutics: Raises $15M in Funding
- Mission Therapeutics focused on selectively inhibiting deubiquitylating enzymes (DUBs), raised $15m (£12m) in equity funding
- Then the round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE)
- All other existing investors (Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Schroders Adveq) joined the round on a pro rata basis
- Mission and Pfizer Inc. have also expanded their relationship by entering into an evaluation and option agreement for DUB target validation
- The company intends to use the funds for the development of its DUB platform, as well as growth of its pipeline of DUB inhibitor programmes
- To date, Mission has received £73m / $101m in funding. and is based at the Babraham Research Campus, Cambridge, UK
